惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

V
Visual Studio Blog
N
Netflix TechBlog - Medium
GbyAI
GbyAI
大猫的无限游戏
大猫的无限游戏
博客园 - 三生石上(FineUI控件)
T
Tailwind CSS Blog
IT之家
IT之家
博客园 - Franky
雷峰网
雷峰网
博客园 - 聂微东
腾讯CDC
M
MIT News - Artificial intelligence
B
Blog RSS Feed
博客园_首页
罗磊的独立博客
S
SegmentFault 最新的问题
I
InfoQ
博客园 - 叶小钗
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
阮一峰的网络日志
阮一峰的网络日志
D
Docker
宝玉的分享
宝玉的分享
B
Blog
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
2026-05-11 · via All Articles on Seeking Alpha

Liquidia Corporation (LQDA) Q1 2026 Earnings Call May 11, 2026 8:30 AM EDT

Company Participants

Jason Adair - Chief Business Officer
Roger Jeffs - CEO & Director
Michael Kaseta - COO & CFO
Russell Schundler - General Counsel & Corporate Secretary
Scott Moomaw - Chief Commercial Officer
Rajeev Saggar - Chief Medical Officer

Conference Call Participants

Amy Li - Jefferies LLC, Research Division
Ryan Deschner - Raymond James & Associates, Inc., Research Division
Serge Belanger - Needham & Company, LLC, Research Division
Julian Harrison - BTIG, LLC, Research Division
Benjamin Burnett - Wells Fargo Securities, LLC, Research Division

Presentation

Operator

Good morning, and welcome to Liquidia Corporation First Quarter 2026 Financial Results and Corporate Update Conference Call. My name is Jonathan, and I will be your operator today. [Operator Instructions] Please note that today's call is being recorded. And now I'd like to turn the call over to Jason Adair, Liquidia's Chief Business Officer. You may proceed.

Jason Adair
Chief Business Officer

Thank you, and good morning, everyone. It's my pleasure to welcome you to our first quarter 2026 financial results and corporate update call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer; Michael Kaseta, Chief Operating Officer and Chief Financial Officer; Dr. Rajeev Saggar, Chief Medical Officer; Scott Moomaw, Chief Commercial Officer; and Rusty Schundler, our General Counsel.

Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties that may cause actual results to differ materially.

For further information, please refer to our filings with the SEC, which are available on our website. Please also note that our earnings release and our commentary include non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures can be found in our earnings